A Form 4 filed on September 16, 2026 with the U.S. Securities and Exchange Commission discloses that Ugur Sahin, Chief Executive Officer of BioNTech SE (NASDAQ:BNTX), sold a combined 49,000 ordinary shares on September 15 and September 16, 2026 pursuant to a pre-established Rule …
Evan Roberts, President of Provider Solutions at Phreesia, Inc. (NYSE:PHR), filed a statement of changes in beneficial ownership on September 16, 2026, reporting the acquisition of 8,113 shares of common stock through restricted stock units granted on September 14, 2026.
A Form 4 filed on September 16, 2026 reports that Amy Beth VanDuyn, SVP of Human Resources at Phreesia, Inc. (NYSE:PHR), acquired 6,490 shares of common stock through a Restricted Stock Unit grant on September 14, 2026, in lieu of a portion of her …
A Form 4 filed on September 16, 2026 disclosed that David Linetsky, President of Network Solutions at Phreesia, Inc. (NYSE:PHR), acquired shares of common stock through fully vested restricted stock units on September 14, 2026.
John A. Cuomo, CEO and President of VSE Corporation (NASDAQ:VSEC), filed a Form 4 on September 16, 2026, disclosing the sale of 1,566 shares of common stock on September 14, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Ralph E. Eberhart, a director of VSE Corp, filed a Form 4 on September 16, 2026, disclosing the acquisition of 67 shares of VSE Corp common stock on September 15, 2026, as part of his quarterly cash retainer for board service.
A Form 4 filed with the SEC on September 16, 2026 discloses that Xu Zhenyu, Chief Scientific Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), sold 4,000 ordinary shares on September 14, 2026 under a Rule 10b5-1 trading plan.
Eric M. Specter, Chief Accounting Officer of Five Below, Inc., reported a sale of 5,500 shares of common stock on September 14, 2026, in a filing submitted to the SEC on September 16, 2026.
Joseph Miller, Vice President and Controller of Consolidated Edison, Inc. (NYSE:ED), filed a Form 4 on September 16, 2026, disclosing a purchase of common stock on September 15, 2026, along with updated beneficial ownership figures.
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA (NASDAQ:SOPH), filed a Form 4 on September 16, 2026, disclosing the sale of 5,000 ordinary shares on September 14, 2026.